Guardant Health Inc. is in talks with advisers for a potential U.S. IPO, Bloomberg News reported, citing people with knowledge of the matter.

The Redwood City, Calif.-based company offers a liquid biopsy assay — marketed as Guardant360 — which uses blood samples to evaluate DNA shed from cancers, instead of an invasive tissue biopsy.

An offering size has not been finalized, but Guardant Health could raise as much as $500 million in the IPO, the sources said. The company can launch a share sale as soon as the fourth quarter.

The company raised $360 million in 2017 in a funding round led by Japanese giant SoftBank Group Corp., along with other investors including Temasek and Sequoia Capital.

Other companies that offer noninvasive ways to detect cancer have attracted big investments, Bloomberg reported. Grail Inc., another cancer-detection startup, is said to be planning an IPO in Hong Kong.